Please assess the completion status of the following clinical trial:

Trial Title: Methadone Versus Morphine for Cancer-Related Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a telephone~* Age: patient must be 18 years or older and less than 70 years of age~* Life expectancy of 3 months or greater~* No prior use of step-3 opioids (step 2 opioids are allowed)~* Provision of informed consent~* Score of 26 or greater on Mini-Mental Status Exam (MMSE) (to be done by investigator if there is question about mental status)~* Nonmalignant pain will be excluded; however, if the patient has both malignant and nonmalignant pain, entry into the trial will be determined by the predominant site of pain~* Moderate to severe cancer related pain that requires the use of step-3 opioids~* Normal renal function~* There will be no exclusionary criteria based on Karnofsky score~* Must live no more than 1 hour away from clinic~* Patient must have pain severity of 5-7/10 on a 0-10 pain scale~Exclusion Criteria:~* Nursing home patients~* Obvious cognitive dysfunction~* Intractable nausea or vomiting~* A true allergy or intolerance to opioids~* Unstable renal function~* Undergoing therapeutic procedures likely to influence pain during the study period~* Gastrointestinal pathology or surgery that influences absorption of morphine or methadone~* Must not have had treatment with radiotherapy, chemotherapy or radionuclides in the last 30 days~* History of drug seeking behavior~* Respiratory compromise~* Treatment with bisphosphonates within the last month~* Use of MAO inhibitors~* Drugs that interfere with CYP34A or CYP2D6~* Drugs that interfere with morphine metabolism~* Retroviral therapies~* Active radiation or antineoplastic therapies~* Hepatic dysfunction~* As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)~* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study~* Study will exclude women who are pregnant and/or nursing~* Women who are of child bearing potential must have a negative urine pregnancy test~* Patients with a recent substance abuse history will be excluded~* Patients with major depression will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Methadone (Type: ACTIVE_COMPARATOR): Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
- Morphine (Type: ACTIVE_COMPARATOR): Oral slow-release morphine (15 mg) every 8 hours, and immediate-release morphine (10 mg) every 4 hours as needed for breakthrough pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).